Caffeine Citrate for the Prevention of Apnea Associated With Alprostadil Infusions

To evaluate the incidence of apnea and requirement for positive pressure ventilation in patients who received caffeine for prevention while receiving alprostadil compared with those who did not receive caffeine. This was a single-center, retrospective study of patients who received alprostadil over...

Full description

Saved in:
Bibliographic Details
Published in:The journal of pediatric pharmacology and therapeutics 2020, Vol.25 (3), p.235-240
Main Authors: Higgins, Kristi L, Buck, Marcia L
Format: Article
Language:English
Subjects:
Clinical Investigations
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the incidence of apnea and requirement for positive pressure ventilation in patients who received caffeine for prevention while receiving alprostadil compared with those who did not receive caffeine. This was a single-center, retrospective study of patients who received alprostadil over a 7-year time frame. Patients were divided into 2 groups based on whether they received caffeine for prevention of apnea while receiving alprostadil. The incidence of apnea and requirements for positive pressure ventilation were recorded. A total of 64 patients who received alprostadil were included for review. Thirty-two patients received caffeine for the prevention of apnea, and 32 patients received alprostadil only. Alprostadil doses were similar between the 2 groups (0.04-0.05 mcg/kg/min). Seven patients had a documented apneic event; 3 in the group given caffeine and 4 in the control group. One patient in each group required intubation because of apnea. All patients with documented apnea were on low-dose alprostadil therapy (
ISSN:1551-6776
2331-348X
DOI:10.5863/1551-6776-25.3.235